Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
Truist Financial Keeps Their Buy Rating on Exelixis (EXEL)
Maintaining Buy Rating on Exelixis Amid Patent Litigation and Strong Growth Prospects
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Envista Holdings (NVST)
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL)
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)
Exelixis Analyst Ratings
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating
Piper Sandler Remains a Buy on Exelixis (EXEL)
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
Exelixis Receives Buy Rating From David Lebovitz on Strong Financials and Growth Prospects
Buy Rating on Exelixis: Growth Prospects Amid Patent Rulings and Pipeline Developments
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Impedimed Limited (OtherIPDQF)
Sell Rating on Exelixis Inc.: Caution Amid Lackluster Growth and Uncertain Product Efficacy
Exelixis Analyst Ratings
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Revvity (RVTY) and Becton Dickinson (BDX)
Exelixis Analyst Ratings
Barclays Reaffirms Their Buy Rating on Exelixis (EXEL)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Exelixis (EXEL) and Fusion Pharmaceuticals (FUSN)
No Data